Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

Barton, Jennifer L.

doi:10.2147/ppa.s5835

Cited by 98 publications

(101 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some biologic DMARDs are given infrequently but require half of a person's work day to administer (e.g., rituximab requires 2 4-hour infusions administered 2 weeks apart every 24 weeks), whereas other treatments are of shorter duration but require more frequent administration (e.g., adalimumab is administered via injection once every 2 weeks). Several studies establish a link between patient preferences and adherence to biologic DMARDs for RA (5). One study (6) reports that the majority of nonadherent RA patients have concerns about their medication, suggesting that understanding patient preferences for RA treatment can help to improve treatment adherence and health outcomes.…”

Section: Introductionmentioning

confidence: 99%

Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments

Poulos

Hauber

González

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Biologic treatments for rheumatoid arthritis (RA) vary widely in both the time required to administer treatment and treatment frequency. This study aimed to quantify the rate at which RA patients are willing to trade off between the time required to administer treatment (duration) and treatment frequency. Methods. Respondents with a self-reported physician diagnosis of moderate to severe RA completed an online discrete choice experiment survey (also known as conjoint analysis). Respondents were presented with a series of treatmentchoice questions. Each hypothetical treatment included 6 attributes: response rate, mode of administration, treatment duration, treatment frequency, and the risks of immediate mild and serious treatment reactions. Preference weights, also called marginal utilities or relative importances, were estimated using mixed-logit methods and then used to calculate the marginal rates of substitution between attributes, including treatment duration and treatment frequency. Results. Among the 901 respondents, 505 were in the RA Information, Service, and Education group (www.risesupport. com) and 396 were members of an online panel. The marginal utility of changes in treatment features was largest for a 1-hour change in treatment duration, while a 1-unit change in the annual frequency of treatment was the second least important change. The marginal utility of changes in annual treatment frequency depends on the treatment duration and vice versa. Conclusion. Respondents would accept treatments with lower efficacy and greater risk to achieve lower duration and frequency. Previous studies have linked patient preferences to treatment adherence, suggesting that reductions in duration or frequency could improve adherence and health outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments

Poulos

Hauber

González

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…In fact, shared decisionmaking, as part of a successful treat-to-target approach [10,42], has been reported to improve patient satisfaction and adherence to medication in autoimmune diseases, allowing patients to achieve optimal management of their condition [48][49][50]. In addition, effective communication between a treating physician and a patient will enable the physician to promptly identify any potential AEs, ultimately leading to desirable clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan

Okazaki¹,

Kobayashi²,

Shimizu³

et al. 2018

Rheumatol Ther

View full text Add to dashboard Cite

“…Most studies focus on pharmacological therapies, with adherence to medication estimated in patients with arthritis at 30-78% (8). In a study of patients with RA taking disease-modifying anti-rheumatic drugs (DMARDs), adherence was estimated at 60-68%, depending on the method used (9).…”

Section: Wwwscandjrheumatoldkmentioning

confidence: 99%

“…By contrast, a database study examining use of biological therapies found poor adherence and high premature discontinuation of therapy (11). Biological therapies are administered by subcutaneous injection or intravenous infusion, which may affect compliance (8,12). Unsurprisingly, poor adherence with medication for RA has been associated with poor outcomes and disease flares (13).…”

Section: Wwwscandjrheumatoldkmentioning

confidence: 99%

How should impaired morning function in rheumatoid arthritis be treated?

Buttgereit

2011

Scandinavian Journal of Rheumatology

View full text Add to dashboard Cite

Patients with rheumatoid arthritis (RA) commonly experience morning symptoms of joint stiffness and pain that result in impaired function. However, current treatment options are limited. The management of impaired morning function is based primarily on non-pharmacological approaches, including simple or short exercises, application of heat or a hot shower or bath, and delaying activities until later in the day. Although it seems that the majority of patients follow the management advice they are given by rheumatologists, symptoms persist. In recent years, only a minority of clinical studies have assessed the impact on morning symptoms of pharmacological treatments for RA. The paucity of data makes it difficult to evaluate systematically the ability of current treatments to improve morning function. However, treatment seems to be suboptimal; in a pan-European survey of 518 rheumatologists, 61% considered that current treatment options do not address impaired morning function specifically, and 68% considered there is a need for new treatment options. Understanding the pathophysiology of circadian symptoms may provide the key to improving treatment of impaired morning function. In patients with morning symptoms of RA, there may be insufficient endogenous cortisol released during the night to counter elevated levels of the pro-inflammatory cytokine, interleukin (IL)-6. Delivering exogenous glucocorticoid during the night was found to reduce IL-6 levels and reduce morning stiffness, but was inconvenient for patients. However, this chronotherapeutic approach has now been facilitated by the development of modified-release prednisone tablets. Taken at bedtime (approximately 10:00 pm), these tablets give programmed delivery of prednisone around 4 h later, at the optimal time to suppress IL-6. Clinical studies suggest that morning stiffness in patients with RA could be treated successfully with the use of low-dose modified-release prednisone.

show abstract

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

Cited by 98 publications

References 41 publications

Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments

Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments

Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan

How should impaired morning function in rheumatoid arthritis be treated?

Contact Info

Product

Resources

About